A post-hoc analysis of the REDEFINE 1 trial suggests that the investigational cagrilintide-semaglutide combination (CagriSema ...
At 48 weeks, participants receiving the highest dose combination of 9 mg eloralintide and 15 mg tirzepatide achieved an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results